Plasma soluble podoplanin is a novel marker for the diagnosis of tumor occurrence and metastasis

Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity

(2017) Mika K. Kaneko et al.   Cancer Medicine

Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin, using glycan-deficient cell lines generated by CRISPR/Cas9 and TALEN

(2017) Mika K. Kaneko et al.   Cancer Medicine

Podoplanin serum and urine concentration in transitional bladder cancer

(2016) Anna Sankiewicz et al.   Cancer Biomarkers

LpMab-12 Established by CasMab Technology Specifically Detects Sialylated O-Glycan on Thr52 of Platelet Aggregation-Stimulating Domain of Human Podoplanin

(2016) Yukinari Kato et al.   PLoS One

Podoplanin is a component of extracellular vesicles that reprograms cell-derived exosomal proteins and modulates lymphatic vessel formation

(2016) Patricia Carrasco-Ramírez et al.   Oncotarget

Podoplanin-expressing cancer-associated fibroblasts lead and enhance the local invasion of cancer cells in lung adenocarcinoma

(2015) Shinya Neri et al.   INTERNATIONAL JOURNAL OF CANCER

Platelet adhesion to podoplanin under flow is mediated by the receptor CLEC-2 and stabilised by Src/Syk-dependent platelet signalling

(2015) Alice Y. Pollitt et al.   THROMBOSIS AND HAEMOSTASIS

The chimeric antibody chLpMab-7 targeting human podoplanin suppresses pulmonary metastasis via ADCC and CDC rather than via its neutralizing activity

(2015) Yukinari Kato et al.   Oncotarget

Detection of EpCAM-positive microparticles in pleural fluid: A new approach to mini-invasively identify patients with malignant pleural effusions

(2015) Elisa Roca et al.   Oncotarget

Podoplanin requires sialylated O-glycans for stable expression on lymphatic endothelial cells and for interaction with platelets

(2014) Y. Pan et al.   BLOOD

A Platform of C-type Lectin-like Receptor CLEC-2 for Binding O -Glycosylated Podoplanin and Nonglycosylated Rhodocytin

(2014) Masamichi Nagae et al.   STRUCTURE

A Cancer-specific Monoclonal Antibody Recognizes the Aberrantly Glycosylated Podoplanin

(2014) Yukinari Kato et al.   Scientific Reports

Podoplanin is a substrate of presenilin-1/γ-secretase

(2013) Maria M. Yurrita et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Platelets Promote Tumor Growth and Metastasis via Direct Interaction between Aggrus/Podoplanin and CLEC-2

(2013) Satoshi Takagi et al.   PLoS One

Chimeric anti-podoplanin antibody suppresses tumor metastasis through neutralization and antibody-dependent cellular cytotoxicity

(2012) Mika Kato Kaneko et al.   CANCER SCIENCE

Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors

(2012) Vidyalakshmi Chandramohan et al.   INTERNATIONAL JOURNAL OF CANCER

The transmembrane domain of podoplanin is required for its association with lipid rafts and the induction of epithelial-mesenchymal transition

(2011) Beatriz Fernández-Muñoz et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Serum carcino-embryonic antigen (CEA) and its possible use as tumor marker for secondary tumors in urinary intestinal reservoirs

(2011) Andreas Loeser et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Platelets regulate lymphatic vascular development through CLEC-2-SLP-76 signaling

(2010) C. C. Bertozzi et al.   BLOOD